Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

Abstract : The mechanism of action of empagliflozin in reducing the risk of adverse cardiovascular outcomes vs placebo in patients with type 2 diabetes mellitus and a high risk of cardiovascular disease in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial is currently unknown. An antiatherosclerotic effect is considered unlikely given the speed of the observed decrease in cardiovascular mortality. Hemodynamic effects, such as reductions in blood pressure and intravascular volume, and involving osmotic diuresis, may provide a more plausible explanation. Metabolic effects, such as cardiac fuel energetics, and hormonal effects, such as increased glucagon release, may also contribute to the results observed during EMPA-REG OUTCOME. This review discusses the main hypotheses suggested to date.
Type de document :
Article dans une revue
The American Journal of Medicine, Elsevier [Commercial Publisher] 2017, 130 (6S), pp.S30-S39. 〈10.1016/j.amjmed.2017.04.009〉
Liste complète des métadonnées

Littérature citée [90 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01533572
Contributeur : Marie-Hélène Derudas <>
Soumis le : mardi 6 juin 2017 - 15:50:55
Dernière modification le : jeudi 20 septembre 2018 - 13:52:02

Fichiers

TheAmerJMed2017Staels.pdf
Publication financée par une institution

Identifiants

Collections

Citation

Bart Staels. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. The American Journal of Medicine, Elsevier [Commercial Publisher] 2017, 130 (6S), pp.S30-S39. 〈10.1016/j.amjmed.2017.04.009〉. 〈inserm-01533572〉

Partager

Métriques

Consultations de la notice

57

Téléchargements de fichiers

178